You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

April 28, 2011

Protecting Drug Patents and Pharmaceutical Data in Asia

Informed Counsel

Today’s patent owners face two significant problems when doing business in Asia: the expiration of their patents and Asia’s generally pro-generic stance on pharmaceuticals.  This article explores the broad concept of “evergreening,” which is even more crucial for companies operating in Asia, and a notable exception to the pro-generic policies in the region, the TRIPS+ or the “exclusive rights” approach.

Related Professionals